These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
190 related items for PubMed ID: 24443791
21. Correlation between a short-term intravenous octreotide suppression test and response to antrectomy in patients with type-1 gastric neuroendocrine tumours. Murugesan SV, Steele IA, Dimaline R, Poston GJ, Shrotri M, Campbell F, Varro A, Pritchard DM. Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):474-81. PubMed ID: 23249603 [Abstract] [Full Text] [Related]
22. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story. Faggiano A. J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846 [Abstract] [Full Text] [Related]
27. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors. Berković MC, Altabas V, Herman D, Hrabar D, Goldoni V, Vizner B, Zjacić-Rotkvić V. Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934 [Abstract] [Full Text] [Related]
28. Everolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: An Indian experience. Tippeswamy R, Patil S, Sateesh CT, Shashidhara HP, Prabhudesai S, Prashanth P, Haridas KM. Indian J Cancer; 2015 Jun; 52(3):359-62. PubMed ID: 26905137 [Abstract] [Full Text] [Related]
33. Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients. de Laat JM, Pieterman CR, van den Broek MF, Twisk JW, Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, Vriens MR, Valk GD. J Clin Endocrinol Metab; 2014 Sep; 99(9):3325-33. PubMed ID: 24915123 [Abstract] [Full Text] [Related]
34. [Octreotide therapy in multiple endocrine neoplasia type-1]. Valkusz Z, Gáspár L, Julesz J, Pávics L. Orv Hetil; 2002 May 12; 143(19 Suppl):1078-81. PubMed ID: 12063865 [Abstract] [Full Text] [Related]
35. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial. Anthony LB, Pavel ME, Hainsworth JD, Kvols LK, Segal S, Hörsch D, Van Cutsem E, Öberg K, Yao JC. Neuroendocrinology; 2015 May 12; 102(1-2):18-25. PubMed ID: 25824001 [Abstract] [Full Text] [Related]